ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma

ClinicalTrials.gov ID: NCT03019640

Public ClinicalTrials.gov record NCT03019640. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 11:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Immunotherapy With Ex Vivo-Expanded Cord Blood-Derived NK Cells Combined With Rituximab High-Dose Chemotherapy and Autologous Stem Cell Transplant for B-Cell Non-Hodgkin's Lymphoma

Study identification

NCT ID
NCT03019640
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
M.D. Anderson Cancer Center
Other
Enrollment
22 participants

Conditions and interventions

Interventions

  • Autologous Hematopoietic Stem Cell Transplantation Procedure
  • Carmustine Drug
  • Cord Blood-derived Expanded Allogeneic Natural Killer Cells Biological
  • Cytarabine Drug
  • Etoposide Drug
  • Filgrastim Biological
  • Lenalidomide Drug
  • Melphalan Drug
  • Rituximab Biological

Procedure · Drug · Biological

Eligibility (public fields only)

Age range
15 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 9, 2017
Primary completion
Aug 15, 2021
Completion
Aug 15, 2021
Last update posted
Feb 15, 2023

2017 – 2021

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
M D Anderson Cancer Center Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03019640, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 15, 2023 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03019640 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →